Arcturus Therapeutics develops messenger RNA medicines and vaccines using its LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies. It has commercialized KOSTAIVE, the world's first approved self-amplifying mRNA COVID-19 vaccine, and advances candidates for rare diseases such as cystic fibrosis and ornithine transcarbamylase deficiency. The company collaborates on additional mRNA vaccine programs and maintains in-house manufacturing expertise.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 24.5 | — | -9.2 | — |
| Q3 2025 | 14.2 | — | -13.4 | — |
| Q4 2025 | 3.1 | — | -29.1 | — |
| Q1 2026 | 0.6 | — | -27 | — |
| Q2 2026 | 0.9 | -96.4% | -23.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Benitec Biopharma Inc. (BNTC), K&F Growth Acquisition Corp. II (KFII), Materialise NV (MTLS), Bleichroeder Acquisition Corp. III (BCCQ), Investar Holding Corporation (ISTR), Gorilla Technology Group Inc. (GRRR)